Contact UsCareers
Top bar

Partners

Expanding our ability to deliver novel cancer therapies that meet the needs of patients with aggressive cancers

Partnering with Ayala

We are always looking to connect with other organizations that share our mission to transform the lives of patients with cancer. Our partnering strategy focuses on expanding our ability to deliver novel cancer therapies that meet the needs of patients with aggressive cancers.

We can’t wait to hear from you. If you are interested in partnering opportunities, reach out via the form below.

Ayala collaborates with companies for the betterment of patients with rare and aggressive cancers.

Our current partners

Bristol

We obtained an exclusive, worldwide license to develop and commercialize AL101 and AL102 from Bristol-Myers Squibb Company, or BMS, in November 2017.

Novartis

We are collaborating with Novartis International Pharmaceutical Limited, or Novartis, to develop AL102 for the treatment of multiple myeloma, or MM, in combination with Novartis’ B-cell maturation antigen, or BCMA, targeting therapies, since 2018.

Explore the two areas we are building out through partnerships.

We actively seek collaboration or licensing opportunities that align with our pipeline, in preclinical and clinical stage.

Asset Licensing: Ayala is looking for oncology assets in Phase 1 or preclinical development that are developed as a monotherapy.

Combinations: We want to connect with companies that could benefit from Notch pathway inhibition by combining gamma secretase inhibitors with their therapies.

We Want To Hear From You

Who would you like to talk to?

Choose from the following options:


Tell us about yourself

The details